drugset / Trial / NCT04682405
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Phase 2
Completed
51 enrolled
Washington University School of Medicine
GlycoMimetics Incorporated · collabThe Foundation for Barnes-Jewish Hospital · collab
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
The investigators hypothesize that prophylactic E-selectin inhibition via administration of uproleselan during melphalan conditioning will reduce the gastrointestinal (GI) toxicity in multiple myeloma (MM) patients undergoing auto-transplant, as assessed via diarrhea severity scoring per CTCAE v5.0, while potentially increasing chemosensitivity of malignant MM cells to high-dose melphalan.
Timeline
- Start
- 2021-05-05
- Primary completion
- 2022-11-11
- Completion
- 2022-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Uproleselan | Small molecule | — | — |
| Background | Melphalan | Small molecule | 200 mg/m2 | — |